Pam Bisikirski - Curative Biotechnology Vice Communications
| CUBT Stock | USD 0.01 0.0003 2.22% |
Executive
Pam Bisikirski is Vice Communications of Curative Biotechnology
| Phone | 561 907 8990 |
| Web | https://curativebiotech.com |
Curative Biotechnology Management Efficiency
The company has return on total asset (ROA) of (0.5178) % which means that it has lost $0.5178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.9828) %, meaning that it created substantial loss on money invested by shareholders. Curative Biotechnology's management efficiency ratios could be used to measure how well Curative Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | EXECUTIVE Age | ||
| Philippe Duchateau | Cellectis SA | 60 | |
| MarieBleuenn Terrier | Cellectis SA | 41 | |
Management Performance
| Return On Equity | -3.98 | ||||
| Return On Asset | -0.52 |
Curative Biotechnology Leadership Team
Elected by the shareholders, the Curative Biotechnology's board of directors comprises two types of representatives: Curative Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Curative. The board's role is to monitor Curative Biotechnology's management team and ensure that shareholders' interests are well served. Curative Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Curative Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul Michaels, President Chairman | ||
| BS BA, Vice Officer | ||
| Pam Bisikirski, Vice Communications | ||
| JD Esq, CFO, CEO | ||
| Ronald Bordens, Executive Board |
Curative Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Curative Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.98 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 13.74 M | ||||
| Shares Outstanding | 903.26 M | ||||
| Shares Owned By Insiders | 0.05 % | ||||
| Price To Sales | 158.53 X | ||||
| Revenue | 132.32 K | ||||
| Gross Profit | 100.21 K | ||||
| EBITDA | (2.5 M) | ||||
| Net Income | (3.96 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Curative Stock Analysis
When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.